Business Context and Reporting Period
This Form 8-K, filed June 10, 2022, reports the results of Ikena Oncology, Inc.’s annual meeting of stockholders held June 9, 2022. The filing identifies Ikena Oncology, Inc. as the registrant, despite the request metadata naming Imagenebio, Inc.
As of the April 14, 2022 record date, the company had 29,947,826 outstanding shares of voting common stock. Ikena’s common stock traded on The Nasdaq Global Market under the symbol IKNA.
Meeting Results
| Proposal | Result |
|---|---|
| Election of Class I directors | Approved; Iain D. Dukes, Maria Koehler, and Otello Stampacchia were elected to three-year terms expiring at the 2025 annual meeting. |
| Ratification of Ernst & Young LLP | Approved as the independent registered public accounting firm for the fiscal year ending December 31, 2022. |
Director Election Votes
| Nominee | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Iain D. Dukes | 23,863,734 | 2,147,337 | 2,466,970 |
| Maria Koehler | 24,597,950 | 1,413,121 | 2,466,970 |
| Otello Stampacchia | 23,333,276 | 2,677,795 | 2,466,970 |
Auditor Ratification Votes
| For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|
| 28,476,524 | 1,095 | 422 | 0 |
Financial Metrics and Material Changes
The filing is limited to annual meeting voting results and does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating metrics, guidance, or comparable-period financial information. No material financial or operating changes are disclosed.
Outlook, Risks, and Unusual Items
No management outlook, guidance, risk update, contingency, transaction, or unusual financial item is reported. The filing confirms that no other matters were submitted to or voted on at the annual meeting.
Investor Verification Points
- Verify that the applicable registrant is Ikena Oncology, Inc.; the supplied metadata refers to Imagenebio, Inc.
- Confirm the three elected Class I directors and their terms through the 2025 annual meeting.
- Confirm Ernst & Young LLP’s ratification for the fiscal year ending December 31, 2022.
- Review the company’s other SEC filings for financial condition, cash runway, operating results, and business outlook, which are not addressed in this Form 8-K.